tigen in culture supernatants without downregulation of HTLV-I tax mRNA expression. Conclusion: Significant involvement with integrin/ligand signaling in extracellular release of HTLV-I virions in cell lines derived from HAM/TSP patients suggests that HTLV-I-infected cells in HAM/TSP patients have the potential for the efficient spread of HTLV-I to uninfected cells.
Introduction
In general, human T lymphotropic virus type I (HTLV-I) infects cells through cell-to-cell contact but not cellfree virions in vivo [1, 2] . Recently, Igakura et al. [3] clearly demonstrated that HTLV-I spreads to cells through the virological synapse, which is composed of adhesion molecules such as integrin and ligand, by polarization of the cytoskeleton, such as the microtubule-organizing center (MTOC). Integrin/ligand signaling induces the activation of small GTPases, such as Rho, Rac and Cdc42, and activation of this signaling pathway is involved in the rearrangement of cytoskeletal components [4, 5] . Of them, Rac and Cdc42 regulate both actin and microtube cytoskeletons, including actin polymerization, cell polarity, and the reorientation of MTOC [6] [7] [8] . Therefore, activation of adhesion molecule signaling induced by the interaction between integrin and its ligand activates MTOC polarization mediated by the activation of both Rac and Cdc42, and the degree of activity of these signaling pathways might determine the efficiency of cell-to-cell spread of HTLV-I.
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic progressive myelopathy characterized by bilateral pyramidal tract involvement with sphincteric disturbances [9] . The primary pathological feature of HAM/TSP is chronic inflammation of the spinal cord characterized by perivascular cuffing and parenchymal infiltration of mononuclear cells [10] . At present, although it is supposed that the destruction of the surrounding nervous tissue induced by the interaction between HTLV-I-infected CD4+ T cells and HTLV-I-specific CD8+ cytotoxic T cells, so-called 'bystander mechanisms', is probably critical in the immunopathological process leading to HAM/TSP [11, 12] , the exact mechanisms underlying chronic myelitis caused by HTLV-I infection are still unknown. We previously reported significantly increased activity of adherence to, and subsequent transmigration through human endothelial cells (EC) of activated CD4+ T cells with heightened lymphocyte function antigen-1 (LFA-1, ␣ L ␤ 2) expression in the peripheral blood T cells of HAM/TSP patients [13, 14] , suggesting that signaling induced by integrin/ligand interaction is upregulated in peripheral blood CD4+ T cells of HAM/TSP patients. Therefore, activation of this signaling itself leading to the activation of small GTPases, as mentioned above, might be related to the efficient cell-to-cell spread of HTLV-I involved in the induction of aberrant immunological functions in HTLV-I-infected cells of the peripheral blood in HAM/ TSP patients.
From these viewpoints, we first analyzed the activity of small GTPases, such as Rho, Rac and Cdc42, in three HTLV-I-infected T cell lines derived from HAM/TSP patients, compared to three HTLV-I-infected T cell lines derived from other origins as controls. When considering cell-to-cell spread of HTLV-I, the extracellular release of HTLV-I virions, that is, HTLV-I production from HTLV-I-infected cells, might be one of the indicators of cell-to-cell spread. If cell-to-cell spread of HTLV-I is regulated by integrin/ligand activity, its efficacy might depend on the release of HTLV-I virions from HTLV-I-infected cells under integrin/ligand interaction. Therefore, secondly, in order to analyze the degree of the involvement of integrin/ligand interaction in the release of HTLV-I virions, we investigated the suppressive effect of HTLV-I production by anti-integrin-blocking antibodies, such as anti-␣ L ␤ 2 and very late-activating antigen-4 (VLA-4, ␣ 4 ␤ 1) antibody, in HTLV-I-infected T cell lines derived from HAM/TSP patients, compared to control cell lines.
Materials and Methods

Cell Lines
HTLV-I-infected T cell lines derived from the cerebrospinal fluid of three different HAM/TSP patients (HCT-1, HCT-4, and HCT-5) were used [15] . These cell lines were IL-2 dependent and maintained in RPMI 1640 containing 20% fetal bovine serum (FBS) supplemented with 100 U/ml of recombinant human IL-2 (kindly provided by Shionogi, Japan). HTLV-I-infected T cell lines (TL-Su, TCL-Kan, and C91/PL) were used as control cell lines. TL-Su, TCL-Kan, and C91/PL were HTLV-I-producing cell lines derived from an HTLV-I asymptomatic carrier, adult peripheral blood, and cord blood, respectively [16] [17] [18] . These cell lines were maintained in RPMI 1640 containing 10% FBS. From flow cytometric analysis of the expression of integrins ( ␣ L ␤ 2 and ␣ 4 ␤ 1) and ligands (ICAM-1 and VCAM-1) in all cell lines, the expression of all integrins/ligands was confirmed except for the weak expression of ␣ 4 ␤ 1 on control cell lines. Our data, such as ICAM-1 and VCAM-1 expression in HTLV-I-infected T cell lines, are consistent with previous reports [19, 20] .
Small GTPase Pull-Down Assay
After each cell line was seeded at 2 ! 10 5 cells/ml, and cultured for 15 h, cells were collected and lysed by ice-cold cell lysis buffer. Pull-down assays for Rho-, Rac-and Cdc42-GTP were performed using Rho, Rac and Cdc42 activation biochem kits, respectively, according to the manufacturer's instructions (Cytoskeleton, Inc., Denver, Colo., USA). Briefly, after cell lysates were clarified by centrifugation, equal amounts of lysates (1 mg per cell line) were incubated with 45 g of Rhotekin-RBD beads for Rho, and 20 g of PAK-PBD beads for Rac and Cdc42 for 1 h on a rotator at 4 ° . The beads were washed, and bound Rho-, Rac-and Cdc42-GTP were subjected to Western blot analysis.
Blocking Study by Anti-Integrin Antibodies
Each cell line was seeded at a concentration of 2 ! 10 5 cells/ml, and cultured in the presence of 20 g/ml of both anti-CD11a/ LFA-1 ( ␣ L ␤ 2) blocking antibody (clone; HI111, BD Biosciences) and anti-␣ 4/CD49d ( ␣ 4 ␤ 1) blocking antibody (clone; 2B4, R&D Systems) or 40 g/ml of control (irrelevant) antibody (clone; MOPC-21, BioLegend) for 15 h. In the time course study, the culture supernatant was collected at 3, 6 and 15 h after the beginning of culture. The culture medium was centrifuged at 2,500 rpm for 10 min and the supernatant was stored at -40 ° until use. In some experiments, cells were collected at 6 and 15 h after the beginning of culture for quantitative RT-PCR study.
Quantitative RT-PCR Analysis
For quantitative analysis of HTLV-I tax mRNA expression, real-time quantitative RT-PCR was performed in a Light-Cycler FastStart DNA Master (Roche Diagnostics, Mannheim, Germany) based on general fluorescence detection with SYBR Green as described previously [21] . Briefly, after total cellular RNA was extracted, cDNA was synthesized from RNA treated with RQ1 RNase-free DNase using Oligo (dT) 12-18 primer (Promega, Madison, Wisc., USA) by M-MLV reverse transcriptase (Promega). The following oligonucleotide primers were used to amplify a 247-bp fragment of HTLV-I tax (forward; AAACA-GCCCTGCAGAGATACAAAGT, reverse; ACTGTAGAGCTG-AGCCGATAACG) and a 236-bp fragment of ␤ -actin (forward; GACGAGGCCCAGAGCAAGAGAG, reverse; ACGTACATG-GCTGGGGTGTTG), respectively. HTLV-I tax mRNA expression was evaluated by normalization to ␤ -actin.
Measurement of HTLV-I p19 Antigen Level in Culture Supernatants
The level of HTLV-I p19 antigen in culture supernatants was measured using the RETROtek HTLV p19 antigen enzyme-linked immunosorbent assay (ELISA) kit following the manufacturer's instructions (Zeptometrix Corporation, Buffalo, N.Y., USA). The amount of HTLV-I p19 antigen was determined in duplicate. The minimum measurable level of HTLV-I p19 antigen was 25.0 pg/ml.
Statistical Analysis
Student's t test was used for statistical analysis. Differences were considered significant at p ! 0.05.
Results
Small GTPases, Particularly Cdc42, Are Strongly Activated in HTLV-I-Infected T Cell Lines Derived from HAM/TSP Patients
As shown in figure 1 , all bound Rho-, Rac-, and Cdc42-GTP were detected in all three HTLV-I-infected T cell lines derived from HAM/TSP patients. However, bound Rho-, Rac-and Cdc42-GTP were detected in only TL-Su of control cell lines. In TL-Su, although the amounts of both bound Rho-and Rac-GTP seemed to be almost the same as in cell lines derived from HAM/TSP patients, the amount of bound Cdc42-GTP was obviously lower than in cell lines derived from HAM/TSP patients, indicating that the degree of activation of Cdc42 is lower in TL-Su than in cell lines derived from HAM/ TSP patients.
HTLV-I Production from HTLV-I-Infected T Cell Lines Derived from HAM/TSP Patients Is Significantly Suppressed by Treatment with Anti-Integrin Blocking Antibodies
As shown in figure 2 , the treatment of HCT-1, HCT-4, and HCT-5 with both anti-␣ L ␤ 2-and anti-␣ 4 ␤ 1-blocking antibodies significantly suppressed the levels of HTLV-I p19 antigen in culture supernatants by about 80, 50 and 50%, respectively. However, the same treatment of TL-Su, TCL-Kan, and C91/PL did not suppress the levels of HTLV-I p19 antigen in culture supernatant ( fig. 2 ) . In order to confirm that anti-integrin-blocking antibodies do not induce the cytotoxic effects for HTLV-I-infected cell lines, we compared the cell viabilities between antiintegrin-blocking antibodies and control antibody-treated cells in each cell line by MTS assay simultaneously. As the results, there were no significant differences between both groups in each cell line (data not shown). These data indicate that HTLV-I production from cell lines derived from HAM/TSP patients, but not control cell lines, is significantly downregulated by the interruption of integrin/ ligand signaling.
Treatment with Anti-Integrin-Blocking Antibodies against HTLV-I-Infected T Cell Lines Derived from HAM/TSP Patients Does Not Induce the Downregulation of HTLV-I Expression
The time course study in HCT-1 treated with anti-␣ L ␤ 2-and anti-␣ 4 ␤ 1-blocking antibodies revealed that a suppressive effect in HTLV-I production was detected at 3 h after the beginning of culture ( fig. 3 ). In addition, as shown in figure 4 , there were no significant differences of HTLV-I tax mRNA expression at 6 and 15 h after the beginning of culture between treatment with anti-␣ L ␤ 2- and anti-␣ 4 ␤ 11-blocking antibodies and control antibody in both HCT-1 and HCT-5. These results strongly suggest that the effect of treatment with anti-integrinblocking antibodies against HTLV-I-infected T cell lines derived from HAM/TSP patients is based on suppression of the extracellular release of HTLV-I virions, but not on the downregulation of HTLV-I expression.
Discussion
In this report, we demonstrated that small GTPases, such as Rho, Rac and Cdc42, are strongly activated in all three HTLV-I-infected T cell lines derived from HAM/ TSP patients. On the other hand, activation of these small GTPases was not detected in control cell lines except TLSu. However, the degree of activation of Cdc42 was obviously lower in TL-Su than in all three cell lines derived from HAM/TSP patients although the activation of both Rho and Rac was almost the same as that of cell lines derived from HAM/TSP patients. HTLV-I-infected cells can interact with each other through integrins and ligands, which are expressed on cells themselves, in our culture systems. Therefore, these data suggest that HTLV-I-infected T cell lines derived from HAM/TSP patients have more activated status of small GTPases, which are the downstream targets of integrin/ligand signaling [5] , than control cell lines. Interestingly, the interruption of integrin/ligand signaling in all three HTLV-I-infected T cell lines derived from HAM/TSP patients, but not all control cell lines, with anti-integrin-blocking antibodies, significantly suppressed HTLV-I production. It was suggested that these phenomena are based on downregulation of the extracellular release of HTLV-I virions, but not HTLV-I expression as follows: (1) a suppressive effect on HTLV-I production of HCT-1 treated with anti-integrin blocking antibodies was detected at 3 h after the beginning of treatment, and (2) there were no significant differences in the mRNA expression of HTLV-I tax in either HCT-1 or HCT-5 between control antibody-treated and anti-integrin-blocking antibody-treated cells at 6 and 
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15 h after the beginning of treatment. These data might indicate that integrin/ligand signaling, which is the upstream of small GTPases, plays an important role in the extracelluar release of HTLV-I virions in HTLV-I-infected T cell lines derived from HAM/TSP patients. Thus, our data suggested that there are, at least, two distinct mechanisms in the extracellular release of HTLV-I virions in HTLV-I-infected cells, such as the system based on the activation of integrin/ligand signaling followed by activation of small GTPases or others. Interestingly, the degree of utilization of the mechanism of integrin/ligand signaling, which plays a crucial role in cell-to-cell spread of HTLV-I through the virological synapse, was higher in HTLV-I-infected T cell lines derived from HAM/TSP patients than in control cell lines during the extracellular release of HTLV-I virions, suggesting that HTLV-I-infected T cell lines derived from HAM/TSP patients have potential for efficient spread of HTLV-I to uninfected cells. However, we need to directly evaluate the efficiency of HTLV-I spread by using the coculture system of HTLV-I-infected T cell lines with noninfected T cell lines. In this study, although Rho, Rac and Cdc42 were activated in TL-Su in the same way as all cell lines derived from HAM/TSP patients, the interruption of integrin/ligand signaling with anti-integrin-blocking antibodies did not suppress HTLV-I production in this cell line. How can this discrepancy be explained? The relatively lower activation of Cdc42, compared to it in cell lines derived from HAM/TSP patients, might be involved. Indeed, Etienne-Manneville and Hall [8] reported that Cdc42 plays an important role, rather than Rac or Rho, in the polarization of MTOC in integrin-mediated activated status in astrocytes. Therefore, HTLV-I-infected T cell lines derived from HAM/TSP patients might have more polarized status of MTOC leading to the extracellular release of HTLV-I virions by utilization of the integrin/ligand signaling pathway although we did not actually analyze the polarized status of MTOC in this study. Our data support the previous results that the polarized condition of MTOC in HTLV-I-infected T cells might depend on Rac or Cdc42 rather than Rho activation [22] .
As HTLV-I-infected cells can interact with each other through integrins and ligands in our culture systems as mentioned above, our data suggest the existence of another molecule, which activates integrin/ligand signaling, in HTLV-I-infected T cell lines derived from HAM/ TSP patients. In this regard, we can confirm the activation of small GTPase Rap1, which is a potent stimulator of integrins as a complex with the regulator of adhesion and cell polarization enriched in lymphoid tissues (RAPL) and facilitates inside-out signaling [23] to easily activate small GTPases, particularly Cdc42, through integrin/ligand signaling leading to MTOC polarization. Therefore, in vivo, HTLV-I-infected cells in HAM/TSP patients might be under the preactivated status of MTOC polarization and this condition might induce the efficient cell-to-cell spread of HTLV-I by contact with non-infected T cells through the virological synapse. Further investigations are underway. It is well known that high HTLV-I proviral load in the peripheral blood is the most important prerequisite in the development of HAM/TSP [24, 25] . The increased proliferation of HTLV-I-infected cells [26, 27] , the relatively lower activity of HTLV-I-specific CD8+ cytotoxic T cells to HTLV-I-infected CD4+ T cells [25] , and the active replication of HTLV-I [28, 29] , etc., are proposed as reasons for the induction of high HTLV-I proviral load in HAM/ TSP patients. Of them, the increased proliferation of HTLV-I-infected cells seems to play an important role mainly in the maintenance of high proviral load in the peripheral blood. However, the efficient cell-to-cell spread by activation of small GTPases in HTLV-I-infected cells might also partially function as one of the factors for the induction of high HTLV-I proviral load in peripheral blood of HAM/TSP patients, although our data presented in this report are based on the analyses in HTLV-I-infected T cell lines derived from HAM/TSP patients.
